Unknown How To Rule With The Help Of Volasertib

In this multivariate setting, intensive salvage was associated with a longer post-relapse survival (HR, 0.57; P?=?0.001), together with CR1 duration more than 12 months http://www.selleckchem.com/products/BI6727-Volasertib.html and ECOG-PS less than 2. Based on a propensity score to be treated intensively, we next performed a one-to-one matching between both salvage subgroups, including the following covariates in the model: age, ECOG-PS, WBC, CR1 duration, prior HSCT, and intermediate versus adverse cytogenetics (CBF-AML were not included). This model allowed matching and comparison of 67 patient pairs. As expected and shown in Table 2(D), paired populations were comparable for all covariates that entered the model. As patients were matched on their propensity to receive an intensive salvage, if post-relapse survival of matched and unmatched patients was similar if treated intensively, unmatched patients had a shorter survival compared to matched patients, if non-intensively treated (P?=?0.45 and 0.028, respectively; Fig. 2A,B). Despite this selection bias (of matched patients http://www.selleckchem.com/products/cb-839.html with a relative better outcome, if non-intensively treated), intensive salvage was associated with a longer post-relapse survival in the matched pair comparison (HR, 0.57; P?=?0.002; Fig. 2C). This benefit associated with intensive salvage remained significant when adjusted to other covariates in the 134 matched patients (HR?=?0.58, P?=?0.004), the other significant factor being the duration of CR1 (HR?=?0.64 for patients with CR1 of 12 months or more, P?=?0.015). Post-relapse survival in these 67 patient pairs, according to intensive versus non-intensive salvage and duration of CR1 http://www.selleck.cn/products/wnt-c59-c59.html (